Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation

Recent advances of antibody drug conjugates for clinical applications

(2020) Pengxuan Zhao et al.   Acta Pharmaceutica Sinica B

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

(2020) Elaine Chang et al.   CLINICAL CANCER RESEARCH

Belantamab Mafodotin: First Approval

(2020) Anthony Markham   DRUGS

PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer

(2019) Samaresh Sau et al.   Cancers

Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy

(2019) Sajad Yaghoubi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Correction to: Polatuzumab Vedotin: First Global Approval

(2019) Emma D. Deeks   DRUGS

Moxetumomab Pasudotox: First Global Approval

(2018) Sohita Dhillon   DRUGS

A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas

(2017) Libin Zhang et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

De-novo and acquired resistance to immune checkpoint targeting

(2017) Nicholas L Syn et al.   LANCET ONCOLOGY

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy

(2016) Panpan Zhang et al.   CANCER SCIENCE

New developments for antibody-drug conjugate-based therapeutic approaches

(2016) Bart ECG de Goeij et al.   CURRENT OPINION IN IMMUNOLOGY

Atezolizumab: First Global Approval

(2016) Anthony Markham   DRUGS

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody

(2016) Tadanobu Nagaya et al.   Oncotarget

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

(2015) L. Apetoh et al.   ANNALS OF ONCOLOGY

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)

(2015) R. M. Sharkey et al.   CLINICAL CANCER RESEARCH

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes

(2011) B. P. Pollack et al.   CLINICAL CANCER RESEARCH